FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)

View source ↗

Summary

FDA approves a supplemental application for LUTATHERA (Lutetium Lu-177 dotatate) filed by Advanced Accelerator Applications USA, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

SUPPL AP for LUTATHERA (LUTETIUM LU 177 DOTATATE)